KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments: 2013-2024

Historic Change in Acquisitions & Divestments for Halozyme Therapeutics (HALO) over the last 12 years, with Dec 2024 value amounting to $395.6 million.

  • Halozyme Therapeutics' Change in Acquisitions & Divestments rose 51.87% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $532.8 million, marking a year-over-year increase of 62.85%. This contributed to the annual value of $395.6 million for FY2024, which is 87.21% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Change in Acquisitions & Divestments is $395.6 million, which was up 87.21% from $211.3 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $746.1 million for FY2022, and its period low was $211.3 million during FY2023.
  • For the 3-year period, Halozyme Therapeutics' Change in Acquisitions & Divestments averaged around $451.0 million, with its median value being $395.6 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Change in Acquisitions & Divestments skyrocketed by 201.24% in 2022 and then crashed by 71.68% in 2023.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Change in Acquisitions & Divestments stood at $306.0 million in 2020, then dropped by 19.05% to $247.7 million in 2021, then surged by 201.24% to $746.1 million in 2022, then slumped by 71.68% to $211.3 million in 2023, then spiked by 87.21% to $395.6 million in 2024.